Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

McKesson's FoxMeyer purchase $400 mil.-$600 mil. below first bid -- FoxMeyer suit.

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

MCKESSON's FOXMEYER PURCHASE $400-$600 MIL. BELOW FIRST BID, FOXMEYER MAINTAINS in seeking $400 mil. in damages from the wholesaler and 10 drug companies for "a conspiracy of events orchestrated" to drive FoxMeyer's wholesaling business into bankruptcy. In a suit filed Jan. 10 in Dallas state court by holding company FoxMeyer Health, the company alleges that McKesson "led [FoxMeyer] to believe" that it would offer "an amount in the range of $400-$600 mil. for FoxMeyer Health's equity interest in FoxMeyer Corp." in August 1995. FoxMeyer decided to sell off its distribution arm in May 1995.

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Accelerated Approval: Withdrawing Gene Therapies Could Be Easier Than Small Molecules

Netherlands Pilots New Scientific Advice Service For Clinical Trials

‘Engage With Us,’ EMA Urges Psychedelic Drug Developers

Pharma Industry Has Shown ‘Huge Interest’ In AI For Drug Development, Says EMA

See All
UsernamePublicRestriction

Register

PS086582

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By